-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI)
Saturday, December 7, 2024: 6:00 PM-9:00 PM
Marina Ballroom D (Marriott Marquis San Diego Marina)
Moderators:
Anita D'Souza, MD, Medical College of Wisconsin and Jorge Monge, MD, University of Colorado Anschutz Medical Campus and Mazie Tsang, MD, Mayo Clinic
Disclosures:
Monge: Janssen: Consultancy; Johnson & Johnson: Consultancy; Pfizer: Consultancy. Tsang: AstraZeneca: Other: Advisory Board; Poseida Therapeutics: Current holder of stock options in a privately-held company; AVEO: Other: Prior holder of stock options in a privately-held company; Novartis: Other: Advisory Board; Genentech: Other: Advisory Board.

The Hematology Inclusion Pathway Presentations and Reception (previously known as Promoting Minorities in Hematology); ASH invites all interested meeting attendees to this event, which will showcase the research of our Hematology Inclusion Pathway awardees. This initiative is a comprehensive 13-year longitudinal career pathway of awards that strives to ensure that hematology reflects and serves the diverse world we live in. The highlight of the session will be oral scientific presentations from program participants.
An Integrated Systems Biology Approach to Understanding the Phenotypic and Functional Diversity of Natural Killer Cells in Cancer

John Roy R Lozada, MD

Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
Engineering Hematopoietic Stem Cells to Generate Therapeutic Antibody Secreting B Cells

Sofia E. Luna

Leland Stanford Stanford Junior University, Stanford, CA
Metabolic Regulation of the Germinal Center Reaction in Chronic Graft Versus Host Disease

Fathima Mohamed

Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
A Role for PSMD3 in Regulating Oxidative Energy Metabolism in Acute Myeloid Leukemia (AML)

Andres J Rubio, MS

Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX
Identifying Mechanisms of Resistance to ATR Inhibition in Myelodysplastic Syndromes with Splicing Factor Mutations

Catherine Gutierrez, MD, PhD

Massachusetts General Hospital, Boston, MA
Retrospective Analysis of the PET/CT Imaging Features of Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL) Patients

Kelly Meza, MD

Baylor College of Medicine, Houston, TX
Retrospective Review of Care for Black/African American Veterans with Multiple Myeloma at the Orlando VA

Joane Titus, MD, MS

HCA Florida Healthcare GME Consortium, University of Central Florida, Orlando, FL
Therapeutic Targeting of JAK/STAT Signaling and Histone Acetyltransferase Activity in Post-Myeloproliferative Neoplasm Secondary AML

Kalay Bertulfo, MS, MA, MPhil

Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY
Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies

Quenton Bubb, MPhil

Leland Stanford Junior University, Stanford, CA
Development of a Novel L-Asparaginase with Enhanced Properties Using Ancestral Sequence Reconstruction

Kristopher Adrian Knight, BS

Molecular and Systems Pharmacology, Emory University, Atlanta, GA
Targeting Aggressive NK-Cell Leukemia and Other CD94-Expressing NK/T-Cell Lymphoproliferative Disorders with CAR T-Cell Therapy

Owhofasa Agbedia

MD Anderson Cancer Center, houston, TX
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>